Inhibiting effects of a cyclic peptide CNGRC on proliferation and migration of tumor cells in vitro

International Journal of Peptide Research and Therapeutics

Volumn 19, Issue 2, 2013, Pages 163-173

  Wei, Yan ^a   Yin, Guangfu ^a   Yin, Hao ^a   Yan, Danhong ^b   Ma, Chuying ^a   Huang, Zhongbing ^a   Liao, Xiaoming ^a   Yao, Yadong ^a   Chen, Xianchun ^a  

^a SICHUAN UNIVERSITY   (China)

^b Chien shiung Institute of Technology   (China)

Author keywords

Migration; NGR; Peptide; Phage display; Tumor cells; Tumor therapeutic

Indexed keywords

CYCLOPEPTIDE; CYSTEINYLASPARAGINYLGLYCYLARGINYLCYSTEINE; MICROSOMAL AMINOPEPTIDASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL SPECIFICITY; CELL VIABILITY; CONTROLLED STUDY; DRUG BINDING; DRUG IDENTIFICATION; DRUG SPECIFICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; UMBILICAL VEIN;

EID: 84878020191     PISSN: 15733149     EISSN: 15733904     Source Type: Journal    
DOI: 10.1007/s10989-012-9327-7     Document Type: Article

References (20)

1. Arap MA (2005) Phage display technology-applications and innovations. Genet Mol Biol 28:1-9
2. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377-380
3. Azzazy HM, Highsmith WE Jr (2002) Phage display technology: clinical applications and recent innovations. Clin Biochem 35:425-445
4. Brown KC (2010) Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Curr Pharm Des 16:1040-1054
5. Chang DK, Lin CT, Wu CH et al (2009) A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS ONE 4:e4171
6. Colombo G, Curnis F, De Mori GM et al (2002) Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 277:47891-47897
7. Corti A, Curnis F, Arap W et al (2008) The neovasculature homing motif NGR more than meets the eye. Blood 112:2628-2635
8. Curnis F, Arrigoni G, Sacchi A et al (2002) Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 62:867-874
9. Curnis F, Longhi R, Crippa L et al (2006) Spontaneous formation of L-isoaspartate and gain of function in fibronectin. J Biol Chem 281:36466-36476
10. Healy JM, Murayama O, Maeda T et al (1995) Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries. Biochemistry 34:3948-3955
11. Hoess RH (2001) Protein design and phage display. Chem Rev 101:3205-3218
12. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases regulators of the tumor microenvironment. Cell 141:52-67
13. Koivunen E, Gay DA, Ruoslahti E (1993) Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem 268:20205-20210
14. Koivunen E, Wang B, Ruoslahti E (1994) Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Biol Chem 124:373-380
15. Krumpe LR, Mori T (2006) The use of phage-displayed peptide libraries to develop tumor-targeting drugs. Int J Pept Res Ther 12:79-91
16. Luan Y, Xu W (2007) The structure and main functions of aminopeptidase N. Curr Med Chem 14:639-647
17. Nilsson F, Tarli L, Viti F, Neri D (2000) The use of phage display for the development of tumor targeting agents. Adv Drug Deliv Rev 43:165-196
18. Paschke M (2006) Phage display systems and their applications. Appl Microbiol Biotechnol 70:2-11
19. Pasqualini R, Ruoslahti E, Kain R et al (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60:722-727
20. Smith GP, Petrenko VA (1997) Phage display. Chem Rev 97:391-410